Tag Archives: breakthrough

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Posted: January 14, 2024 at 2:35 am

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —

Read more from the original source:
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Posted in Global News Feed | Comments Off on HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status